Prostate cancer test shows greater sensitivity:
This article was originally published in Clinica
Horus Global HealthNet and Speciality Laboratories are to jointly market Horus' ProstAsure computer-assisted test for prostate cancer. The system combines weighted factors for prostate specific antigen (PSA), prostatic acid phosphatase, total creatine kinase and the patient's age. Horus claims this gives a more sensitive and stable indicator of the disease than PSA alone (see Clinica No 705 p 16). Trials showed that the device had a 75% sensitivity and specificity in detecting prostate cancer in men with a normal PSA of less than 4.0ng/ml.